Cite
HARVARD Citation
Pujol, J. et al. (2016). Safety and Immunogenicity of the PRAME Cancer Immunotherapeutic in Patients with Resected Non–Small Cell Lung Cancer: A Phase I Dose Escalation Study. Journal of thoracic oncology. 11 (12), p. . [Online].